ArticleeLife2025
Human multiethnic radiogenomics reveals low-abundancy microRNA signature in plasma-derived extracellular vesicles for early diagnosis and molecular subtyping of pancreatic cancer.
Article in eLife, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Review
- Machine learning for extracellular vesicles enables diagnostic and therapeutic nanobiotechnology.Journal of nanobiotechnology · 2026Review
- Extracellular vesicle biomarkers: current status and future perspectives as novel tools in liquid biopsy.Frontiers in immunology · 2026Review
- Conditioned Media-Derived Tumor Extracellular Vesicles: Bridging Molecular Insights and Therapeutic Applications in Oncology.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Pancreatic cancer (PC) is a highly aggressive malignancy in humans, where early diagnosis significantly improves patient outcomes. However, effective methods for accurate and early detection remain limited. In this multiethnic study involving human subjects, we developed a liquid biopsy signature based on extracellular vesicle (EV)-derived microRNAs (miRNAs) linked to radiomics features extracted from patients' tumor imaging. We integrated eight datasets containing clinical records, imaging data of benign and malignant pancreatic lesions, and small RNA sequencing data from plasma-derived EVs of PC patients. Radiomics features were extracted and analyzed using the limma package, with feature selection conducted via the Boruta algorithm and model construction through Least Absolute Shrinkage and Selection Operator regression. Radiomics-related low-abundance EV miRNAs were identified via weighted gene co-expression network analysis and validated for diagnostic accuracy using 10 machine-learning algorithms. Three key EV miRNAs were found to robustly distinguish malignant from benign lesions. Subsequent molecular clustering of these miRNAs and their predicted targets identified two PC subtypes, with distinct survival profiles and therapeutic responses. Specifically, one cluster was associated with prolonged overall survival and higher predicted sensitivity to immunotherapy, while the other indicated high-risk tumors potentially amenable to targeted drug interventions. This radiogenomic EV miRNA signature in human plasma represents a promising non-invasive biomarker for early diagnosis and molecular subtyping of PC, with potential implications for precision treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.